Combination of Chemoradiation Therapy and Epitope Peptide Vaccine Therapy in Treating Patients With Esophageal Cancer
- Conditions
- Esophageal Cancer
- Interventions
- Biological: URLC10, TTK, KOC1, VEGFR1, VEGFR2, cisplatin, fluorouracil
- Registration Number
- NCT00632333
- Lead Sponsor
- Teikyo University
- Brief Summary
The purpose of this study is to evaluate the safety and immune response of multiple peptides (URLC10, TTK, KOC1 VEGFR1, and VEGFR2) emulsified with Montanide ISA51 in combination with chemotherapy (CDDP, 5-FU) plus radiation therapy in treating patients with unresectable, advanced or recurrent esophageal cancer.
- Detailed Description
Up-regulated ling cancer 10 (URLC10), TTK protein kinase (TTK) and K homology domain containing protein over expressed in cancer (KOC1) were identified as new targets of tumor associated antigens using cDNA microarray technologies combined with the expression profiles of normal and cancer tissues. Furthermore, anti-angiogenic therapy is now considered to be one of promising approaches for treating cancer. Vascular endothelial growth factor receptor 1 (VEGFR1) and vascular endothelial growth factor receptor 2 (VEGFR2) are essential targets for tumor angiogenesis. Epitope peptides for these targets are able to induce cytotoxic T lymphocytes (CTL) restricted to HLA-A \*2402 in vivo. On the other hand, chemotherapy (CDDP, 5-FU) plus radiation therapy has been to be a standard treatment for unresectable advanced esophageal cancer. In this clinical trial, we evaluate the safety and immune responses of different doses of multiple peptides (URLC10, TTK, KOC1, VEGFR1, and VEGFR 2) emulsified with Montanide ISA 51 in combination with chemotherapy (CDDP, 5-FU) plus radiation therapy in treating patients with unresectable, advanced or recurrent esophageal cancer.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 9
-
Patients must have unresectable, locally advanced, recurrent or metastatic disease of esophageal cancer.
-
measurable disease by CT scan
-
ECOG performance status of 0 to 2
-
Expected survival of at lease 3months
-
Patients must be HLA-A2402
-
Laboratory values as follow:
- WBC > 2000/mm3,
- Platelet count > 75000/mm3,
- Total bilirubin < 1.5 x the institutional normal upper limits,
- Creatinine < 1.5 x the institutional normal upper limits,
- AST. ALT. ALP < 2.5 x the institutional normal upper limits
-
Able and willing to give valid written informed consent
- Pregnancy (women of childbearing potential:Refusal or inability to use effective means of contraception)
- Breastfeeding
- Active or uncontrolled infection
- Prior chemotherapy,radiation therapy or immunotherapy within 4 weeks
- Concurrent treatment with steroid or immunosuppressing agent
- Patient with peptic ulcer disease
- Active or uncontrolled other malignancy
- Other malignancy within 5 years prior to entry into the study, expect for treated non-melanoma skin cancer and cervical carcinoma in situ
- Disease to the central nervous system
- Decision of unsuitableness by principal investigator or physician-in-charge
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description 1 URLC10, TTK, KOC1, VEGFR1, VEGFR2, cisplatin, fluorouracil -
- Primary Outcome Measures
Name Time Method Safety(toxicities as assessed by NCI CTCAE version3) 3 months
- Secondary Outcome Measures
Name Time Method Peptide specific CTL induction 3 months DTH to peptide 3 months Changes in levels of regulatory T cells 3 months Objective response rate as assessed by RECIST criteria 1 year Time to progression 1 year survival 1 year
Trial Locations
- Locations (1)
Teikyo University
🇯🇵2-11-1 Kaga Itabashi-ku, Tokyo, Japan